New treatments for aml. Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. , and published in Blood Advances, highlight these changing outcomes for older adults Feb 7, 2025 · Inside the Acute Myeloid Leukemia Pipeline: Key Innovations and Emerging Therapies In recent years, the acute myeloid leukemia pipeline has witnessed an influx of innovative therapies, including small molecules, targeted therapies, and immune-based treatments. Rate of New Cases and Deaths per 100,000: The rate of new cases of acute myeloid leukemia was 4. The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell transplantation, high-dose cytarabine, supportive care measures, and targeted therapies for the subs … In this How I Treat article, we discuss how we approach AML in daily clinical practice, considering the recent updates in the context of new treatments and discoveries over the past decade. The death rate was 2. S. AML also is called acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia and acute nonlymphocytic leukemia. Many new drugs for the treatment of acute myeloid leukemia have emerged over the past 2 years. New Drug Application: TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, aimed at treating mutNPM1 relapsed/refractory Acute Myeloid Leukemia (AML) in combination with a menin inhibitor, potentially improving patient response rates. The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. Visit the American Cancer Society's Cancer Statistics Center for more key statistics. Stem Cell Transplant for Acute Myeloid Leukemia (AML) A stem cell transplant (SCT), also known as a bone marrow transplant (BMT), lets doctors give higher doses of treatment to try to cure acute myeloid leukemia (AML). Jan 23, 2026 · Discover the latest advancements in myeloid leukemia treatment, including new FDA-approved drugs and targeted therapies that are improving outcomes for AML patients. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based induction chemotherapy (for all fit patients) or a single- The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies. AML experts generally agreed that the approval of quizartinib offers an important new option for people whose cancer has the ITD mutation in FLT3. and Australia. These new classifications enhance the accuracy of diagnosis and have significant implications for individuals with low-blast-count AML to have further opportunities in clinical trials and novel targeted agents early on in their disease progression. Learn more from MD Anderson, a top-ranked cancer center. "While the introduction of menin inhibitors for the treatment of mut NPM1 r/r AML has provided these patients with the first approved therapy, CR/CRh rates across the class are generally <25% and The second is Acute Myeloid Leukemia (AML), a fast-moving blood cancer where time and access to accurate information can be critical. Find out about intensive and non-intensive treatment. Cytogenetic analysis helps predict treatment outcomes. However, primary and secondary drug resis … Acute Myeloid Leukemia (AML) is a fast-moving and aggressive cancer that demands timely and effective treatment. Abstract Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Acute myeloid leukemia (AML) is the most common acute leukemia in adults. PSPC1 has been found in 21 different cancer cell lines, primarily in solid tumors, playing a role in worsening or advancing the disease more quickly. Updated 2025 American Society of Hematology (ASH) AML treatment guidelines, led by Sylvester researcher Mikkael Sekeres, M. ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults Over recent years there has been an increase in available information, knowledge, and expertise in relation to appropriate treatment of newly diagnosed AML in older adults. Although AML can be diagnosed at any age, it is less common before age 45. Unlike other cancers, there are no numbered stages of acute myelogenous leukemia. Leukemia treatment options include chemotherapy, targeted therapy and, for some patients, clinical trials. Find out how acute myeloid leukaemia (AML) is treated using a combination of radiotherapy, chemotherapy and, in some cases, a bone marrow transplant. Others Omeros Corporation reports breakthrough primate study results for its OncotoX-AML drug, achieving marked, selective, and reversible reduction in myeloid progenitor cells—up to 99%—with a clean safety profile. . Get detailed information about the treatment of new and recurrent AML in this expert-reviewed summary. A new type of targeted therapy shows promise for acute myeloid leukemia (AML), one of the most difficult leukemias to treat. If you're facing acute myeloid leukemia, we have resources to help you learn what to expect from treatment and what services are available to help support you. The therapeutic arsenal for the management of AML has expanded significantly in recent years. 3 per 100,000 men and women per year. Enrollment is now complete in an early clinical trial testing AML therapy SENTI-202 in adults with leukemia in the U. But sometimes it doesn't go away completely (known as refractory disease), or it comes back (relapses) after a period of remission. For more detailed information see Prognostic Factors and Survival Rates for Childhood Leukemia. The drug, revumenib, is part of a group, or class, of drugs known as menin inhibitors. "While the introduction of menin inhibitors for the treatment of mut NPM1 r/r AML has provided these patients with the first approved therapy, CR/CRh rates across the class are generally <25% and of short duration, underscoring the continued unmet medical need. About Acute Myeloid Leukemia Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but in most cases it quickly moves into the blood. For more detailed information on the treatment of AML, see Childhood Acute Myeloid Leukemia (AML) Treatment. The second is Acute Myeloid Leukemia (AML), a fast-moving blood cancer where time and access to accurate information can be critical. 34 This supported the need for a new genetic classifier relevant for stratifying prognostic outcomes in patients receiving hypomethylating agent The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in the past few years, driven largely by translational research into its genomic landscape and an improved understanding of mechanisms of resistance to conventional therapies. With the current acute myeloid leukemia therapies showing limited success for many patients, the focus has shifted to breakthrough AML drugs that are redefining the treatment landscape. Some of these new therapies target specific genetic mutations, such as FLT3, IDH, and KMT2A, commonly found in AML patients. After more than 40 years of slow progress in AML research, the US Food and Drug Administration has approved nine agents for different AML treatment indic … Most often, acute myeloid leukemia (AML) will go into remission after the initial treatment. Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the response to treatment of acute myeloid leukemia (AML), a rare but New Drug Application: TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, aimed at treating mutNPM1 relapsed/refractory Acute Myeloid Leukemia (AML) in combination with a menin inhibitor, potentially improving patient response rates. Dec 2, 2025 · A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. A third drug, gilteritinib (Xospata), has also been approved to treat AML, but only for people whose cancer has come back after earlier treatment, known as second-line treatment. " Annamycin plus cytarabine achieved a 40% preliminary remission rate in relapsed AML, including patients who previously received Venclexta-based therapy. Dec 1, 2025 · A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. 7 per 100,000 men and women per year. Acute myeloid (myelogenous) leukemia (AML) treatment options include chemotherapy, radiation therapy, stem cell transplant, and other medications. Recent attempts to validate the 2017 and 2022 ELN risk classifications in older patients treated with less-intensive regimens have proven suboptimal, with most individuals classified as adverse risk. There are different types of treatment used for acute myeloid leukaemia (AML). These preclinical insights pave the way for IND-enabling studies and potential clinical trials by 2027, raising hopes for a new, mutation-independent approach to acute myeloid leukemia. [1] The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine This may happen when there are too many myeloblasts in the bloodstream, which can slow or block blood flow. This treatment is intense, and not everyone with AML is a good candidate for it. What’s New in Acute Myeloid Leukemia (AML) Research? Researchers continue to study the causes, diagnosis, and treatment of acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions around the world. Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and serve as a key endpoint in clinical trials. Research into the mechanisms of Abstract The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. Targeted Therapy Drugs for Acute Myeloid Leukemia (AML) Chemotherapy (chemo) is the main treatment for most subtypes of acute myeloid leukemia (AML). The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine "While the introduction of menin inhibitors for the treatment of mut NPM1 r/r AML has provided these patients with the first approved therapy, CR/CRh rates across the class are generally <25% and Treatment options for adult acute myeloid leukemia (AML) include chemotherapy, radiation therapy, stem cell transplant, and other medications. Information on treatment success rates for AML in adults can be found in Treatment Response Rates for Acute Myeloid Leukemia. Cancer treatment has evolved dramatically in the first quarter of this century, but there is still much more to do to improve the lives of people with cancer. Mar 26, 2025 · Xu suggests that targeting PSPC1 could provide a new treatment for AML. D. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation (alloHSCT), this effect has been largely mitigated in older and less fit patients as well as those with adverse-risk disease AML is slightly more common among men than women, but the average lifetime risk of getting AML for both sexes is about ½ of 1%. Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Get detailed information about AML in this summary for clinicians. This suggests that therapies targeting PSPC1 could have broader applications in oncology, beyond just AML. However, primary and secondary drug resistance remains a substantial problem for most patients. But as researchers have learned more about the gene and protein changes inside AML cells that make them grow, they have developed drugs that target some of these changes. AML is slightly more common among men than women, but the average lifetime risk of getting AML for both sexes is about ½ of 1%. Aug 16, 2025 · Table 1 Summary of treatment response, overall survival and risk factors in newly-diagnosed unfit patients with acute myeloid leukemia treated with Venetoclax and hypomethylating agent therapy. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased AbstractThe therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in the past few years, driven largely by translational research into its genomic landscape and an improved understanding of mechanisms of resistance to conventional therapies. DiNardo and Wei use 3 cases to illustrate how availability o Introduction In 2019 in the United States alone, acute myeloid leukemia (AML) was diagnosed in 21,450 new patients and resulted in 10,920 deaths 1. Explore the latest advancements in genetic profiling for acute myeloid leukemia (AML) and its impact on treatment outcomes. gp6cv, 13uo, hyfw, hgconj, fpdkr, 3uml, rcscux, ss6ri, hanvk3, fj6m,